INTRODUCTION: The sigma-1 receptor (Sig-1R) is a unique ligand-regulated molecular chaperone that interacts with several protein targets such as G protein-coupled receptors and ion channels to modulate their activity. Sig-1R is located in areas of the central and peripheral nervous system that are key to pain control. Previous preclinical studies have suggested a potential therapeutic use of Sig-1R antagonists for the management of neuropathic pain. DISCUSSION: Recent studies using pharmacological and genetic tools have explored the role of Sig-1R in inflammatory pain conditions. Mice lacking the Sig-1R have shown different patterns of phenotypic responses to inflammatory injury. Systemic or peripheral administration of several Sig-1R antagonists, including the selective Sig-1R antagonist S1RA, inhibited both mechanical and thermal hypersensitivity in several preclinical models of inflammatory pain. These recent studies are summarized in the present commentary. CONCLUSION: Central and peripheral pharmacological blockade of Sig-1R could be an effective option to treat inflammatory pain.
INTRODUCTION: The sigma-1 receptor (Sig-1R) is a unique ligand-regulated molecular chaperone that interacts with several protein targets such as G protein-coupled receptors and ion channels to modulate their activity. Sig-1R is located in areas of the central and peripheral nervous system that are key to pain control. Previous preclinical studies have suggested a potential therapeutic use of Sig-1R antagonists for the management of neuropathic pain. DISCUSSION: Recent studies using pharmacological and genetic tools have explored the role of Sig-1R in inflammatory pain conditions. Mice lacking the Sig-1R have shown different patterns of phenotypic responses to inflammatory injury. Systemic or peripheral administration of several Sig-1R antagonists, including the selective Sig-1R antagonist S1RA, inhibited both mechanical and thermal hypersensitivity in several preclinical models of inflammatory pain. These recent studies are summarized in the present commentary. CONCLUSION: Central and peripheral pharmacological blockade of Sig-1R could be an effective option to treat inflammatory pain.
Authors: Cruz Miguel Cendán; José Miguel Pujalte; Enrique Portillo-Salido; Lluís Montoliu; José M Baeyens Journal: Eur J Pharmacol Date: 2005-03-21 Impact factor: 4.432
Authors: Georgia Gris; Manuel Merlos; José M Vela; Daniel Zamanillo; Enrique Portillo-Salido Journal: Behav Pharmacol Date: 2014-06 Impact factor: 2.293
Authors: José Manuel Entrena; Enrique José Cobos; Francisco Rafael Nieto; Cruz Miguel Cendán; Georgia Gris; Esperanza Del Pozo; Daniel Zamanillo; José Manuel Baeyens Journal: Pain Date: 2009-04-17 Impact factor: 6.961
Authors: Beatriz de la Puente; Xavier Nadal; Enrique Portillo-Salido; Ricard Sánchez-Arroyos; Sergio Ovalle; Gabriel Palacios; Asunción Muro; Luz Romero; José Manuel Entrena; José Manuel Baeyens; José Antonio López-García; Rafael Maldonado; Daniel Zamanillo; José Miguel Vela Journal: Pain Date: 2009-06-07 Impact factor: 6.961
Authors: Trine Hjørnevik; Peter W Cipriano; Bin Shen; Jun Hyung Park; Praveen Gulaka; Dawn Holley; Harsh Gandhi; Daehyun Yoon; Erik S Mittra; Greg Zaharchuk; Sanjiv S Gambhir; Christopher R McCurdy; Frederick T Chin; Sandip Biswal Journal: J Nucl Med Date: 2017-06-01 Impact factor: 10.057
Authors: Alba Vidal-Torres; Begoña Fernández-Pastor; Alicia Carceller; José Miguel Vela; Manuel Merlos; Daniel Zamanillo Journal: Front Pharmacol Date: 2019-04-24 Impact factor: 5.810
Authors: Ángeles Montilla-García; Miguel Á Tejada; M Carmen Ruiz-Cantero; Inmaculada Bravo-Caparrós; Sandra Yeste; Daniel Zamanillo; Enrique J Cobos Journal: Front Pharmacol Date: 2019-02-22 Impact factor: 5.810
Authors: Daehyun Yoon; Angela M Fast; Peter Cipriano; Bin Shen; Jessa B Castillo; Christopher R McCurdy; Carina Mari Aparici; Deirdre Lum; Sandip Biswal Journal: Front Pain Res (Lausanne) Date: 2021-10-20
Authors: Timur A Mavlyutov; Tyler Duellman; Hung Tae Kim; Miles L Epstein; Charlotte Leese; Bazbek A Davletov; Jay Yang Journal: Neuroscience Date: 2016-06-23 Impact factor: 3.590